Regulus Therapeutics Inc. announced today that the European Patent Office (EPO) and United States Patent and Trademark Office (USPTO) have recently granted claims for microRNA-122 therapy in hepatitis ...

LA JOLLA, Calif., July 23, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, ...

SAN DIEGO, June 27, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

Approximately two weeks ago the S&P 500 finally broke through its 2065 resistance. At the same time, the Nasdaq Composite pushed above its 4800 resistance. Expectations at that time would have been ...

On March 20, 2014, the bright asteroid Regulus will "wink" out when it is eclipsed (or "occulted") by the huge asteroid 163 Erigone. It is an extremely rare celestial event only visible from a slim ...

SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

When you buy through links on our articles, Future and its syndication partners may earn a commission. Credit: Gianluca Masi/Virtual Telescope Project. Graphic created in Canva by Daisy Dobrijevic ...

SAN DIEGO, Jan. 2, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...